LUNG CANCER

Edward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, discussed the use of adjuvant therapies including chemotherapy and osimertinib in patients with non–small cell lung cancer.

In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.

Wellmarker Bio’s novel therapeutic antibody WM-A1-3389 will be tested with Merck’s pembrolizumab in a phase 1b study of patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed the CheckMate 9LA and KEYNOTE-407 trials of chemotherapy combined with immunotherapy in patients with advanced squamous cell lung cancer.

In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.

Joshua K. Sabari, MD, discusses his use of durvalumab in the frontline setting for the treatment of patients with small-cell lung cancer and where he sees the role for the treatment.

Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.

Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.

Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.

Mark Socinski, MD and Joshua Sabari, MD review the key efficacy data from the KRYSTAL 1b cohort and discusses strategies for managing adverse events seen with adagrasib.

Drs Socinski and Sabari discuss the emergence of the KRAS12C mutation, specifically in patients with CNS metastases and how this factors into their treatment decision.

Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.

Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.

Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,

Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line cemiplimab in managing PD-L1–high metastatic NSCLC.

Comprehensive insight to factors that inform the optimal selection of first-line therapy for patients with PD-L1–high metastatic non–small cell lung cancer.

Expert oncologist Marina Chiara Garassino, MD, reflects on a patient case of PD-L1–high metastatic NSCLC and outlines first-line treatment options in this setting.

Results from the phase 3 PEARLS/KEYNOTE-091 trial have led to the FDA approval of adjuvant pembrolizumab for the treatment fully resected NSCLC.

Nathan Pennell, MD, PhD, discusses the importance of developing drugs based on resistance to previous treatments in patients with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.

The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.

A focused discussion on whether immunotherapy might be an effective treatment option for patients with RET-positive mNSCLC.

The panel reviews LIBRETTO-001 and ARROW safety data on selpercatinib and pralsetinib in RET fusion-positive mNSCLC, and share their clinical experience in adverse event (AE) management in patients who are receiving one of these therapies.

Dr Piotrowska outlines the RET tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib, which are available for patients with RET fusion-positive mNSCLC, then Dr Neal follows with a discussion of supporting efficacy data from the LIBRETTO-001 and ARROW trials.